Hospital
Banner Baywood Medical Center
Banner Baywood Medical Center was paid $29.69M by Medicaid between Jan 2018 and Dec 2024, across 270 billing codes. Its largest line is 99285, emergency room visit (most serious) — 36% of everything it billed.
33Billing provider infoBANNER BAYWOOD MEDICAL CENTER
MESA, AZ 85206
MESA, AZ 85206
33aNPI1194758284assigned 07/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$29.69M
24GClaims1,069,545
24DCodes billed270
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#15 of 78
Median peer was paid$12.21M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 166,942 | $4.64M | |
| 2019 | 154,149 | $4.51M | |
| 2020 | 132,738 | $4.10M | |
| 2021 | 149,001 | $4.11M | |
| 2022 | 168,847 | $4.62M | |
| 2023 | 165,605 | $4.38M | |
| 2024incomplete | 132,263 | $3.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 36% | 32,935 | 28,580 | $10.71M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 28,064 | 25,334 | $5.14M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 10.0% | 5,546 | 5,135 | $2.96M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.5% | 15,239 | 14,175 | $2.52M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.9% | 5,527 | 5,051 | $1.74M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 3.9% | 1,670 | 1,487 | $1.16M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 3.0% | 998 | 896 | $881K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 9,204 | 8,130 | $585K |
| C1776 | Joint device (implantable) | 1.7% | 434 | 377 | $517K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.5% | 3,087 | 2,722 | $437K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 4,116 | 3,851 | $354K |
| G0378 | Hospital observation service, per hour | <1% | 14,681 | 7,426 | $279K |
258 more codes
| 80053 | Comprehensive metabolic panel | <1% | 57,260 | $232K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,819 | $199K |
| 27447 | <1% | 37 | $183K | |
| 49083 | <1% | 553 | $149K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 10,686 | $140K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 92 | $102K |
| 36430 | <1% | 569 | $102K | |
| 29580 | <1% | 4,171 | $90K | |
| 47562 | <1% | 27 | $80K | |
| 70496 | <1% | 149 | $77K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,403 | $58K |
| 93971 | <1% | 1,861 | $52K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,401 | $50K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 115 | $49K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,727 | $45K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,776 | $45K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 260 | $44K |
| 72131 | <1% | 165 | $43K | |
| 49650 | <1% | 12 | $41K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 34,570 | $39K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 27,063 | $37K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 603 | $35K |
| 29445 | <1% | 406 | $32K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 23,065 | $31K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 111 | $30K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 4,631 | $26K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,710 | $25K |
| 74174 | <1% | 29 | $25K | |
| 71250 | <1% | 385 | $22K | |
| 95811 | <1% | 28 | $17K | |
| 93970 | <1% | 101 | $17K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 323 | $17K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,189 | $16K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,903 | $16K |
| 96376 | <1% | 9,482 | $15K | |
| 70486 | <1% | 176 | $14K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,798 | $14K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,139 | $10K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 40 | $9K |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 214 | $9K |
| 80320 | <1% | 4,757 | $9K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 104 | $8K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,702 | $8K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,120 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,830 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,911 | $7K |
| 87075 | <1% | 541 | $6K | |
| C1781 | Mesh (implantable) | <1% | 128 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,518 | $6K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $5K |
| 85610 | <1% | 25,671 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 91 | $5K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 59,448 | $5K |
| 71045 | Radiologic examination, chest; single view | <1% | 24,963 | $4K |
| 36591 | <1% | 2,259 | $4K | |
| 10060 | <1% | 28 | $4K | |
| 36416 | <1% | 5,450 | $4K | |
| 93976 | <1% | 571 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 264 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 129 | $3K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 155 | $3K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 12 | $3K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 4,595 | $2K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,144 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 681 | $2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,106 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,004 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 14 | $2K |
| 70498 | <1% | 187 | $2K | |
| J3490 | Unclassified drugs | <1% | 29,180 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,262 | $2K |
| C1769 | Guide wire | <1% | 998 | $1K |
| 81025 | <1% | 4,061 | $1K | |
| 87040 | <1% | 9,506 | $1K | |
| 84484 | <1% | 25,610 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,057 | $1K |
| 84703 | <1% | 6,701 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,501 | $1K |
| 73562 | <1% | 1,700 | $1K | |
| 87631 | <1% | 903 | $1K | |
| 73610 | <1% | 1,237 | $975.68 | |
| 73630 | <1% | 1,409 | $964.88 | |
| 82947 | <1% | 22,265 | $896.63 | |
| 81001 | <1% | 16,149 | $890.42 | |
| 83690 | <1% | 16,666 | $796.94 | |
| 73130 | <1% | 986 | $698.32 | |
| 73502 | <1% | 1,016 | $628.44 | |
| 96367 | <1% | 1,213 | $545.66 | |
| 84702 | <1% | 3,019 | $541.08 | |
| 86923 | <1% | 452 | $538.31 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,249 | $532.30 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,014 | $504.66 |
| 83605 | <1% | 12,506 | $502.28 | |
| 73030 | <1% | 1,474 | $473.47 | |
| 83880 | <1% | 7,310 | $470.70 | |
| 72170 | <1% | 306 | $467.73 | |
| 87186 | <1% | 3,338 | $441.25 | |
| 83735 | <1% | 16,287 | $434.91 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 497 | $425.47 |
| 81003 | <1% | 7,784 | $420.87 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 460 | $390.44 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,527 | $387.50 |
| 82803 | <1% | 648 | $378.15 | |
| 76770 | <1% | 14 | $372.86 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,221 | $364.80 |
| 80329 | <1% | 589 | $330.20 | |
| A9270 | Non-covered item or service | <1% | 62,796 | $286.16 |
| 76801 | <1% | 53 | $271.86 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 302 | $261.93 |
| 85027 | <1% | 6,749 | $251.47 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,027 | $232.72 |
| 90715 | <1% | 1,017 | $222.43 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,438 | $221.34 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 588 | $218.71 |
| 87088 | <1% | 6,398 | $207.18 | |
| 85730 | <1% | 5,020 | $206.11 | |
| 99152 | <1% | 767 | $201.51 | |
| 87070 | <1% | 1,930 | $190.07 | |
| 86850 | <1% | 3,395 | $173.15 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13,179 | $170.48 |
| 94760 | <1% | 4,451 | $166.17 | |
| 87077 | <1% | 3,985 | $162.81 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,232 | $155.53 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 57 | $152.73 |
| 73110 | <1% | 394 | $152.30 | |
| 82565 | <1% | 775 | $147.12 | |
| 84132 | <1% | 2,417 | $146.82 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,760 | $136.68 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 28,234 | $135.28 |
| 80061 | Lipid panel | <1% | 492 | $121.37 |
| 85014 | <1% | 1,826 | $106.24 | |
| 85379 | <1% | 2,160 | $105.02 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 101 | $100.67 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,272 | $100.29 |
| G0379 | Direct admission of patient for hospital observation care | <1% | 129 | $96.22 |
| 72100 | <1% | 129 | $92.98 | |
| 85018 | <1% | 2,056 | $87.12 | |
| 97161 | <1% | 2,351 | $85.95 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,364 | $69.59 |
| 85055 | <1% | 1,891 | $68.46 | |
| 82550 | <1% | 3,767 | $65.86 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,107 | $63.38 |
| 86140 | <1% | 3,095 | $59.85 | |
| J1815 | Injection, insulin, per 5 units | <1% | 4,528 | $56.24 |
| 84439 | <1% | 840 | $52.71 | |
| 74018 | <1% | 346 | $49.26 | |
| 82728 | <1% | 320 | $46.58 | |
| 87205 | <1% | 2,032 | $46.48 | |
| 93041 | <1% | 314 | $41.05 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,760 | $40.14 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,080 | $38.34 |
| 97116 | <1% | 2,180 | $36.59 | |
| 82010 | <1% | 269 | $36.48 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,024 | $29.78 |
| 88342 | <1% | 198 | $29.56 | |
| 85652 | <1% | 1,617 | $29.21 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,200 | $28.12 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,481 | $27.51 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 3,324 | $27.40 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,846 | $27.00 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,368 | $26.68 |
| 84145 | <1% | 373 | $26.30 | |
| 86901 | <1% | 3,704 | $25.41 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,383 | $25.30 |
| 86900 | <1% | 3,532 | $22.78 | |
| 96368 | <1% | 263 | $22.78 | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,219 | $18.81 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 961 | $18.48 |
| 82140 | <1% | 1,247 | $15.20 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,567 | $15.18 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,568 | $14.82 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 494 | $14.66 |
| 73590 | <1% | 29 | $12.48 | |
| 12001 | <1% | 40 | $12.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 165 | $10.40 |
| 99153 | Mod sedat endo service >5yrs | <1% | 663 | $10.09 |
| J7999 | Compounded drug, not otherwise classified | <1% | 544 | $7.24 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,599 | $6.97 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,632 | $6.63 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 124 | $6.43 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 802 | $6.32 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,153 | $5.93 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,123 | $5.06 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 230 | $4.08 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,081 | $2.92 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,343 | $1.94 |
| 84100 | <1% | 2,490 | $1.36 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,767 | $1.34 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 206 | $0.67 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,917 | $0.47 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 106 | $0.01 |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 92 | $0.01 |
| 83540 | 0% | 78 | $0.00 | |
| 85520 | 0% | 203 | $0.00 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 380 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 170 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 797 | $0.00 |
| 89051 | 0% | 206 | $0.00 | |
| 94664 | 0% | 586 | $0.00 | |
| 51701 | 0% | 262 | $0.00 | |
| 84520 | 0% | 234 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 426 | $0.00 |
| P9016 | Red blood cells, leukocytes reduced, each unit | 0% | 479 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 1,043 | $0.00 |
| 84295 | 0% | 208 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 104 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 185 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 245 | $0.00 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 0% | 465 | $0.00 |
| 84466 | 0% | 64 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 18 | $0.00 |
| 36600 | 0% | 47 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 125 | $0.00 |
| J0735 | Injection, clonidine hydrochloride, 1 mg | 0% | 53 | $0.00 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 0% | 40 | $0.00 |
| 87102 | 0% | 16 | $0.00 | |
| 76937 | 0% | 43 | $0.00 | |
| 51702 | 0% | 50 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 12 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 19 | $0.00 |
| 88304 | 0% | 559 | $0.00 | |
| 97165 | 0% | 710 | $0.00 | |
| 82435 | 0% | 153 | $0.00 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 201 | $0.00 |
| 94761 | 0% | 72 | $0.00 | |
| 87206 | 0% | 40 | $0.00 | |
| 73560 | 0% | 40 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 123 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 1,221 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 99 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 262 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 567 | $0.00 |
| 74021 | 0% | 69 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 14 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 94 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 157 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 200 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 14 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 147 | $0.00 |
| 90686 | 0% | 116 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 510 | $0.00 |
| 82553 | 0% | 117 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 140 | $0.00 |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 12 | $0.00 |
| 82330 | 0% | 31 | $0.00 | |
| 88307 | 0% | 158 | $0.00 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 18 | $0.00 |
| 12002 | 0% | 13 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 26 | $0.00 |
| 82607 | 0% | 14 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 32 | $0.00 |
| 87116 | 0% | 13 | $0.00 | |
| 70544 | 0% | 24 | $0.00 | |
| 83615 | 0% | 14 | $0.00 | |
| 71101 | 0% | 36 | $0.00 | |
| J1836 | Injection, metronidazole, 10 mg | 0% | 18 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 12 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKELLAR, BRIAN (CEO)
Parent organizationBANNER HEALTH
| Provider | Location | Paid |
|---|---|---|
| Banner Ironwood Medical Center | Queen Creek, AZ | $29.40M |
| Banner Goldfield Medical Center | Apache Junction, AZ | $18.63M |
| Banner Heart Hospital | Mesa, AZ | $340K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.